Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1043 participants.

Also called NCT02052310

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,043 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02052310
  • EudraCT 2013-002753-30
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Bulgaria, Chile, Colombia, Latvia, Malaysia, Mexico, Poland, Romania, Russia, South Korea, Taiwan, Thailand, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02052310. Randomized; no masking; primary purpose treatment. Start 2014-02-11 (actual); primary completion 2018-09-21 (actual). Results posted on 2021-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Acronym
Himalayas
Condition
Anemia in Incident Dialysis Patients
Intervention (Drug)
Roxadustat
Intervention (Drug)
Epoetin Alfa
Lead sponsor
Kyntra Bio (class: industry)
Collaborator
Astellas Pharma Europe B.V. (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02052310
Content hash
360fc8780ebb864584070a5f2a9c79738090ac8355a9652218da667ecc61b481